Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency.
It has been reported that in allogeneic stem cell transplantation, the mannan-binding lectin (MBL) status of the donor has prognostic value for the recipient. Two MBL-deficient patients, with coexisting haematological malignancy, were identified who were treated with bone marrow from donors with normal MBL concentrations. Although both patients engrafted successfully and remain in complete remission, neither seroconverted to the MBL sufficiency status of his donor over a follow-up period exceeding 2 years. This does not support the concept of MBL replacement by stem cell therapy, and does not provide an explanation for high MBL concentrations in stem cell donors protecting recipients from post transplant infections.
Kilpatrick
D C
DC
SNBTS National Science Laboratory, Ellen's Glen Road, Edinburgh EH17 7QT, UK. dave.kilpatrick@snbts.csa.scot.nhs.uk
Stewart
K
K
Allan
E K
EK
McLintock
L A
LA
Holyoake
T L
TL
Turner
M L
ML
D000328:Adult; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000628:therapy*; D007239:Infections / Q000209:etiology; D008297:Male; D037601:Mannose-Binding Lectin / Q000097:blood / Q000172:deficiency*; D008875:Middle Aged; D012074:Remission Induction; D014019:Tissue Donors; D016896:Treatment Outcome
D037601:Mannose-Binding Lectin